More T cell receptors to the RAScue in cancer?
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci184782 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Eric Tran. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment with T cells genetically engineered to express tumor-reactive T cell receptors (TCRs), known as TCR-gene therapy (TCR-T), is a promising immunotherapeutic approach for patients with cancer. The identification of optimal TCRs to use and tumor antigens to target are key considerations for TCR-T. In this issue of the JCI, Bear and colleagues report on their use of in vitro assays to characterize four HLA-A*03:01- or HLA-A*11:01-restricted TCRs targeting the oncogenic KRAS G12V mutation. The TCRs were derived from healthy donors or patients with pancreatic cancer who had received a vaccine against mutant KRAS. The most promising TCRs warrant testing in patients with KRAS G12V-positive cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Tran, E. (2024). More T cell receptors to the RAScue in cancer?. Journal of Clinical Investigation. https://doi.org/10.1172/jci184782
Vancouver
Tran E. More T cell receptors to the RAScue in cancer?. Journal of Clinical Investigation. 2024. doi:10.1172/jci184782
BibTeX
@article{Tran2024,
author = {Tran, Eric},
title = {More T cell receptors to the RAScue in cancer?},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci184782}
}
EUVIMED